Pathology of multiple sclerosis

Where do we stand?

Bogdan F Gh Popescu, Istvan Pirko, Claudia F Lucchinetti

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Purpose of Review: This article summarizes the pathologic features of multiple sclerosis (MS) and other inflammatory demyelinating diseases and discusses neuropathologic studies that have yielded novel insights into potential mechanisms of demyelination. Recent Findings: The pathologic hallmark of MS consists of focal demyelinated plaques within the CNS, with variable degrees of inflammation, gliosis, and neurodegeneration. Active MS lesions show a profound pathologic heterogeneity with four major patterns of immunopathology, suggesting that the targets of injury and mechanisms of demyelination in MS may be different in different disease subgroups. Recent pathologic studies have suggested that the subarachnoid space and cortex may be initial sites and targets of the MS disease process, that inflammatory cortical demyelination is present early in MS, and that meningeal inflammation may drive cortical and white matter injury in some MS patients. Summary: MS is heterogeneous with respect to clinical, genetic, radiographic, and pathologic features; surrogate MRI, clinical, genetic, serologic, and/or CSF markers for each of the four immunopatterns need to be developed in order to recognize them in the general nonbiopsied MS population. Inflammatory cortical demyelination is an important early event in the pathogenesis of MS and may be driven by meningeal inflammation. These observations stress the importance of developing imaging techniques able to capture early inflammatory cortical demyelination in order to better understand the disease pathogenesis and to determine the impact of potential diseasemodifying therapies on the cortex.

Original languageEnglish (US)
Pages (from-to)901-921
Number of pages21
JournalCONTINUUM Lifelong Learning in Neurology
Volume19
Issue number4
DOIs
StatePublished - Aug 2013

Fingerprint

Multiple Sclerosis
Pathology
Demyelinating Diseases
Inflammation
Subarachnoid Space
Gliosis
Wounds and Injuries
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Pathology of multiple sclerosis : Where do we stand? / Popescu, Bogdan F Gh; Pirko, Istvan; Lucchinetti, Claudia F.

In: CONTINUUM Lifelong Learning in Neurology, Vol. 19, No. 4, 08.2013, p. 901-921.

Research output: Contribution to journalArticle

Popescu, Bogdan F Gh ; Pirko, Istvan ; Lucchinetti, Claudia F. / Pathology of multiple sclerosis : Where do we stand?. In: CONTINUUM Lifelong Learning in Neurology. 2013 ; Vol. 19, No. 4. pp. 901-921.
@article{8c4206ea3e3d410bae4e1cb123d32b21,
title = "Pathology of multiple sclerosis: Where do we stand?",
abstract = "Purpose of Review: This article summarizes the pathologic features of multiple sclerosis (MS) and other inflammatory demyelinating diseases and discusses neuropathologic studies that have yielded novel insights into potential mechanisms of demyelination. Recent Findings: The pathologic hallmark of MS consists of focal demyelinated plaques within the CNS, with variable degrees of inflammation, gliosis, and neurodegeneration. Active MS lesions show a profound pathologic heterogeneity with four major patterns of immunopathology, suggesting that the targets of injury and mechanisms of demyelination in MS may be different in different disease subgroups. Recent pathologic studies have suggested that the subarachnoid space and cortex may be initial sites and targets of the MS disease process, that inflammatory cortical demyelination is present early in MS, and that meningeal inflammation may drive cortical and white matter injury in some MS patients. Summary: MS is heterogeneous with respect to clinical, genetic, radiographic, and pathologic features; surrogate MRI, clinical, genetic, serologic, and/or CSF markers for each of the four immunopatterns need to be developed in order to recognize them in the general nonbiopsied MS population. Inflammatory cortical demyelination is an important early event in the pathogenesis of MS and may be driven by meningeal inflammation. These observations stress the importance of developing imaging techniques able to capture early inflammatory cortical demyelination in order to better understand the disease pathogenesis and to determine the impact of potential diseasemodifying therapies on the cortex.",
author = "Popescu, {Bogdan F Gh} and Istvan Pirko and Lucchinetti, {Claudia F}",
year = "2013",
month = "8",
doi = "10.1212/01.CON.0000433291.23091.65",
language = "English (US)",
volume = "19",
pages = "901--921",
journal = "Continuum (Minneapolis, Minn.)",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Pathology of multiple sclerosis

T2 - Where do we stand?

AU - Popescu, Bogdan F Gh

AU - Pirko, Istvan

AU - Lucchinetti, Claudia F

PY - 2013/8

Y1 - 2013/8

N2 - Purpose of Review: This article summarizes the pathologic features of multiple sclerosis (MS) and other inflammatory demyelinating diseases and discusses neuropathologic studies that have yielded novel insights into potential mechanisms of demyelination. Recent Findings: The pathologic hallmark of MS consists of focal demyelinated plaques within the CNS, with variable degrees of inflammation, gliosis, and neurodegeneration. Active MS lesions show a profound pathologic heterogeneity with four major patterns of immunopathology, suggesting that the targets of injury and mechanisms of demyelination in MS may be different in different disease subgroups. Recent pathologic studies have suggested that the subarachnoid space and cortex may be initial sites and targets of the MS disease process, that inflammatory cortical demyelination is present early in MS, and that meningeal inflammation may drive cortical and white matter injury in some MS patients. Summary: MS is heterogeneous with respect to clinical, genetic, radiographic, and pathologic features; surrogate MRI, clinical, genetic, serologic, and/or CSF markers for each of the four immunopatterns need to be developed in order to recognize them in the general nonbiopsied MS population. Inflammatory cortical demyelination is an important early event in the pathogenesis of MS and may be driven by meningeal inflammation. These observations stress the importance of developing imaging techniques able to capture early inflammatory cortical demyelination in order to better understand the disease pathogenesis and to determine the impact of potential diseasemodifying therapies on the cortex.

AB - Purpose of Review: This article summarizes the pathologic features of multiple sclerosis (MS) and other inflammatory demyelinating diseases and discusses neuropathologic studies that have yielded novel insights into potential mechanisms of demyelination. Recent Findings: The pathologic hallmark of MS consists of focal demyelinated plaques within the CNS, with variable degrees of inflammation, gliosis, and neurodegeneration. Active MS lesions show a profound pathologic heterogeneity with four major patterns of immunopathology, suggesting that the targets of injury and mechanisms of demyelination in MS may be different in different disease subgroups. Recent pathologic studies have suggested that the subarachnoid space and cortex may be initial sites and targets of the MS disease process, that inflammatory cortical demyelination is present early in MS, and that meningeal inflammation may drive cortical and white matter injury in some MS patients. Summary: MS is heterogeneous with respect to clinical, genetic, radiographic, and pathologic features; surrogate MRI, clinical, genetic, serologic, and/or CSF markers for each of the four immunopatterns need to be developed in order to recognize them in the general nonbiopsied MS population. Inflammatory cortical demyelination is an important early event in the pathogenesis of MS and may be driven by meningeal inflammation. These observations stress the importance of developing imaging techniques able to capture early inflammatory cortical demyelination in order to better understand the disease pathogenesis and to determine the impact of potential diseasemodifying therapies on the cortex.

UR - http://www.scopus.com/inward/record.url?scp=84881625770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881625770&partnerID=8YFLogxK

U2 - 10.1212/01.CON.0000433291.23091.65

DO - 10.1212/01.CON.0000433291.23091.65

M3 - Article

VL - 19

SP - 901

EP - 921

JO - Continuum (Minneapolis, Minn.)

JF - Continuum (Minneapolis, Minn.)

SN - 1080-2371

IS - 4

ER -